The project is intended to assess ML-10's contribution in accelerating clinical development of cancer therapies. The initial term of the nonexclusive collaboration with GSK is for two years and can be extended on certain conditions. Financial terms were not disclosed.
Aposense begins trial, December 15, 2008
NeuroSurvival Technologies gets financing, changes name, August 20, 2008
IBA, NeuroSurvival Technologies partner, August 14, 2008
NST is cleared for Aposense trials, July 25, 2008
Copyright © 2009 AuntMinnie.comIf you like this content, please share it with a colleague!